T lymphocyte responses in HIV-1 infection: implications for vaccine development.
about
HIV-1 Nef impairs MHC class II antigen presentation and surface expressionCD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjectsSimultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence.Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail.Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motifQuintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine designRapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assayCD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjectsThe HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individualsComprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 allelesEfficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice.The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesProtective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS modelStructure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques.Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.Retinoid-dependent restriction of human immunodeficiency virus type 1 replication in monocytes/macrophagesSpecific therapy regimes could lead to long-term immunological control of HIV.Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trialPersistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection.Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection.Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques.Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cellsA heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.The flexibility of the TCR allows recognition of a large set of naturally occurring epitope variants by HIV-specific cytotoxic T lymphocytes.MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population.
P2860
Q22248080-F9DBFF31-BB19-4829-8CFE-182D645E9F8DQ24798701-C2411A16-9B39-413C-964B-753C51434B04Q24814428-C3923895-2F39-4130-BDA0-68BC99D950E2Q33570433-C33A7CE4-09B7-467C-A9A4-38D0E7506C46Q33813011-BD9AF5F6-4213-4D5D-8F76-41E23DFCF9B0Q33834814-9C47E1E6-D2E3-466A-A835-F6852EA90745Q33836117-E02ADE5D-D86E-42A3-BC25-507E8DADDDF4Q33839044-6DD4A4CD-01BB-4931-9BFB-2188817783D6Q33839981-E328A3AA-DBBF-46B8-A230-51BB35410EEEQ33842152-F23DDF65-FCC7-45E7-BA8F-29DEF568B863Q33845527-30231BB2-5F3E-4D11-A293-6A3370C27436Q33850281-B8C957BC-7A2C-4908-A1D4-E1C8A5DAC2C2Q33874266-913A65D7-9012-4D6C-878D-1AF4AF407B40Q33998262-561CFC99-60FC-4415-9E9F-A3C3881EE2D7Q34104267-34CEA6A9-C649-49FE-B90C-13FF1EF43D81Q34339044-E5B8B956-EFB7-4626-BB96-075AE61553EAQ34474562-59A3AEFA-5620-42A6-9D14-20A83AB2F325Q34535707-F6C5FC86-0CA2-4CD5-9403-1D2B2EEEB72DQ34781685-EF8098E2-8F69-40A5-9DDE-15C9202DDD16Q34970873-592E848D-CF52-49B1-BD1A-BEAF6AE8CFCBQ35803633-250BCF65-3E14-4630-9FD0-13B3AA6D307AQ36010016-C0B60128-FD1A-4E0F-B9BE-A064FCD3DF0EQ36314997-7FE4C95A-7BCB-49E3-B0CF-2004CBE3D288Q36369035-62266346-34AC-4CBC-9704-14E1C41E6A2FQ36509253-9FFE0639-5DFE-4BA9-9BBC-8E62D5D5C29FQ36746170-8749B87E-FBDB-4386-9C0C-092669A1369BQ36934021-DC77DB21-9901-47E7-9924-D7CE87E06F08Q36943282-0F760D8A-95DD-4457-8452-D252D605CCA5Q36954486-63D70F45-F832-4C46-AF12-095718116298Q37092653-FC653E99-814E-4B29-9A6D-FBC8092A9376Q37191948-40A17B52-49B2-440F-8CF1-422306B30A1CQ37333878-19DFBF56-E11B-42AC-A153-6AEA52765FCAQ37568241-F36F4AA7-F487-4182-979D-7823B14EF2A9Q39602544-8FD57229-2CC4-4C90-A46B-08850F4CCAD8Q40220988-BD153CFC-07A1-4EFA-89DB-C18291B65A80Q40795693-9DDD0F44-2B84-40CD-910C-902FA4B4E046Q40822849-B62F883F-FAB2-4F4F-BBE7-DFA1FA7CC384Q45423710-8DA51D99-7792-409E-89B2-C1C2E12EA757Q47573209-048DA58D-2615-459F-B18A-9A8F4CF68D7D
P2860
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@ast
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@en
type
label
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@ast
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@en
prefLabel
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@ast
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@en
P1476
T lymphocyte responses in HIV-1 infection: implications for vaccine development.
@en
P2093
P304
P356
10.1016/S0952-7915(99)80076-4
P577
1999-08-01T00:00:00Z